Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans

Vahid Feiz; Lisa Nijm; Randolph D. Glickman; Lawrence S. Morse; David G. Telander; Susanna S. Park; Christopher R. Polage; Steven M. Christiansen; Majid Moshirfar

doi:10.1097/ICO.0b013e318298ddf8

Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans

Vahid Feiz, Lisa Nijm, Randolph D. Glickman, Lawrence S. Morse, David G. Telander, Susanna S. Park, Christopher R. Polage, Steven M. Christiansen, Majid Moshirfar

Ophthalmology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt

Original language	English (US)
Pages (from-to)	1315-1320
Number of pages	6
Journal	Cornea
Volume	32
Issue number	10
DOIs	https://doi.org/10.1097/ICO.0b013e318298ddf8
State	Published - Oct 1 2013

Keywords

Aqueous
Bactrim
Endophthalmitis
Sulfamethoxazole
Trimethoprim
Vitrectomy
Vitreous

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/ICO.0b013e318298ddf8

Fingerprint Dive into the research topics of 'Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans'. Together they form a unique fingerprint.

Cite this

Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans. / Feiz, Vahid; Nijm, Lisa; Glickman, Randolph D.; Morse, Lawrence S.; Telander, David G.; Park, Susanna S.; Polage, Christopher R.; Christiansen, Steven M.; Moshirfar, Majid.

In: Cornea, Vol. 32, No. 10, 01.10.2013, p. 1315-1320.

Research output: Contribution to journal › Article › peer-review

@article{b03418bf7438428caaf3a24999951e6f,

title = "Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans",

abstract = "Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt",

keywords = "Aqueous, Bactrim, Endophthalmitis, Sulfamethoxazole, Trimethoprim, Vitrectomy, Vitreous",

author = "Vahid Feiz and Lisa Nijm and Glickman, {Randolph D.} and Morse, {Lawrence S.} and Telander, {David G.} and Park, {Susanna S.} and Polage, {Christopher R.} and Christiansen, {Steven M.} and Majid Moshirfar",

year = "2013",

month = oct,

day = "1",

doi = "10.1097/ICO.0b013e318298ddf8",

language = "English (US)",

volume = "32",

pages = "1315--1320",

journal = "Cornea",

issn = "0277-3740",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans

AU - Feiz, Vahid

AU - Nijm, Lisa

AU - Glickman, Randolph D.

AU - Morse, Lawrence S.

AU - Telander, David G.

AU - Park, Susanna S.

AU - Polage, Christopher R.

AU - Christiansen, Steven M.

AU - Moshirfar, Majid

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt

AB - Purpose: To determine the penetration of orally administered trimethoprim (TMP)-sulfamethoxazole (SMX) into the aqueous and vitreous cavity of noninflamed human eyes. Methods: Nine adult patients undergoing cataract surgery and 10 adult patients undergoing pars plana vitrectomy were given 3 doses of oral TMP-SMX every 12 hours before the surgery. Aqueous and blood samples were collected from patients undergoing cataract surgery; vitreous and blood samples were collected from patients undergoing vitrectomy. The levels of TMP and SMX were analyzed using high-performance liquid chromatography and were compared with the mean minimum inhibitory concentrations (MIC90) of potential ocular pathogens. Results: TMP-SMX was present in all samples. Among eyes undergoing cataract surgery, the mean concentrations of TMP in aqueous and blood were 0.341 ± 0.141 μg/mL (mean ± SD) and 1.501 ± 0.433 μg/mL and of SMX were 5.259 ± 0.929 μg/mL and 11.835 ± 2.100 μg/mL, respectively. Among eyes undergoing vitrectomy, the mean concentrations of TMP in vitreous and blood were 1.864 ± 0.807 μg/mL and 4.591 ± 2.979 μg/mL and of SMX were 5.910 ± 2.705 μg/mL and 39.289 ± 15.469 μg/mL, respectively. MIC90 levels were achieved against many bacterial pathogens, including methicillin-resistant Staphylococcus aureus. Conclusions: TMP-SMX penetrates both the aqueous and vitreous cavities when given orally. The components reach therapeutic inhibitory concentrations in the ocular cavity against many potential pathogens. Copyrigt

KW - Aqueous

KW - Bactrim

KW - Endophthalmitis

KW - Sulfamethoxazole

KW - Trimethoprim

KW - Vitrectomy

KW - Vitreous

UR - http://www.scopus.com/inward/record.url?scp=84886098908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886098908&partnerID=8YFLogxK

U2 - 10.1097/ICO.0b013e318298ddf8

DO - 10.1097/ICO.0b013e318298ddf8

M3 - Article

C2 - 23928948

AN - SCOPUS:84886098908

VL - 32

SP - 1315

EP - 1320

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 10

ER -

Vitreous and aqueous penetration of orally administered trimethoprim-sulfamethoxazole combination in humans

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this